Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).
Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), has announced a new strategic partnership with ADC Biotechnology, a UK based company specializing in antibody-drug conjugates (ADCs).
Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.
WuXi Biologics expands its biologics conjugation solution center to include space for commercial manufacturing of antibody-drug conjugates for the biopharma industry.